Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 13/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1873673 | 0.90 | BRAF (0.49) | BRAFCYP2C9 | |
| SCHEMBL1871902 | 0.87 | PTGS1 (0.38) | BRAFPTGS1PTGS2 | |
| SCHEMBL26089296 | 0.81 | BRAF (0.46) | BRAF | |
| SCHEMBL3882959 | 0.79 | GAA (0.37) | — | |
| SCHEMBL1868409 | 0.79 | BRAF (0.41) | BRAFKCNA5ADRA1AKCNK3CYP2C9 | |
| SCHEMBL1876513 | 0.78 | BRAF (0.39) | BRAFCYP2C9PTGS1PTGS2 | |
| SCHEMBL12669237 | 0.78 | BRAF (0.51) | BRAFCYP2C9 | |
| SCHEMBL9987523 | 0.76 | BRAF (0.48) | BRAFKCNA5KCNK3CYP2C9 | |
| SCHEMBL24761235 | 0.76 | ERCC5 (0.47) | CYP2C9 | |
| SCHEMBL29751913 | 0.76 | ERCC5 (0.47) | CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2585454-A1 | HETEROARYL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | Novartis AG (CH) | 2013-05-01 | — | — | EP | disclosed |
| US-20130096149-A1 | HETEROARYL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | disclosed |
| EP-2498608-A1 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | GlaxoSmithKline LLC (US) | 2012-09-19 | — | — | EP | disclosed |
| WO-2011161216-A1 | HETEROARYL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011059610-A1 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011059610-A1 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096149-A1 | HETEROARYL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | BRAF, RAF1, ARAF | BRAF 1/4885KCNA5 2628/4885CTPS1 2963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.